Although 2020 was a tough year for the biopharma industry — and most other industries as well — it appeared to rebound significantly in mid-2021. However, biotech stocks are generally getting hammered during 2022, although to be fair, the entire stock market is down.
The U.S. Securities and Exchange Commission (SEC) added 12 China companies to their delisting watchlist.
Halozyme Therapeutics announced that the company is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47 percent in premarket trading on April 13.
Sanofi plans to list the company’s drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.
Seattle-based Icosavax’s stock plunged more than 60 percent on March 25 after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
Five Chinese companies face potential delisting from Wall Street if they fail to comply with new audit orders from the U.S. Securities and Exchange Commission (SEC).
Synairgen’s inhalable therapy failed in late-stage trial testing in patients hospitalized with COVID-19, wiping out over 85% of the British drugmaker’s stock value on February 21 after the blow to the development of the company’s key product.
Over the past six months, the Nasdaq Biotechnology Index has declined more than 20%. Some of the falling prices appear to be due to some investors losing interest in many companies that soared into favor during the COVID-19 pandemic. And these companies that have seen declining investor interest are now struggling to raise finances, according to BioSpace
Eli Lilly is in the news for positive Olumiant data in Covid-19, a drop in Covid-19 product sales for second-quarter 2021, and a protest of one of the company’s ads.
The first half of 2021 saw a flurry of IPOs as multiple companies make the move to become publicly traded.